Patient Deaths Stop Infinity Pharma’s Phase III HSP90 Trial In Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Sicker patients may have led to result in GI stromal tumors; lung, breast studies with IPI-504 continue.